In This Section      

Search Results

E1910 A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Protocol Number:
Phase III
Keith Pratz
Johns Hopkins Kimmel Cancer Center in Baltimore
This research is being done to determine what affects (good and bad) the therapy blinatumomab has on your type of cancer (BCR/ABL negative ALL). This new therapy will be added to what has traditionally been used to treat your specific sub-type of ALL. Studies are being done in ALL and other blood cancers with blinotumomab. It is hoped that blinatumomab will target your B-cell ALL and destroy these specific cells, but it has not yet been proven.
People between the ages of 35 and 70 years and have been recently diagnosed with a subtype of acute lymphoblastic leukemia (ALL) that is known as BCR-ABL negative B-lineage ALL may join.
There are several steps of treatment in this study. They are called induction, intensification, consolidation, and maintenance. In these study steps you will be getting standard chemotherapy treatments that may or may not be combined with a new cancer drug called blinatumomab. Your doctor may recommend you to have a blood or marrow transplant (BMT) at a later date after randomization to the blinatumomab/no blinatumomab arms, if you have a suitable donor.
Last Update
03/05/2019 05:03 AM